A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants that have advanced or metastatic breast cancer (BC), or advanced or metastatic colorectal cancer (CRC). All participants in this study will take the study medication (PF-08032562) as pill by mouth. This will be repeated for 28-day cycles. Depending on which part of the s

Trial Details

NCT ID

NCT07318805

Phase

PHASE1

Sponsor

Pfizer

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

PF-08032562
Fulvestrant
Cetuximab
Fluorouracil
Oxaliplatin
Leucovorin

Locations (sample)

Duarte, California, United States|34.13945,-117.97729
Grand Rapids, Michigan, United States|42.96336,-85.66809
Conroe, Texas, United States|30.31188,-95.45605
Houston, Texas, United States|29.76328,-95.36327
Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

18 years of age or older
Advanced or metastatic cancer of the breast or colon Part 1A: metastatic or advanced breast cancer or colorectal cancer for which no standard thera…
Measurable disease
ECOG performance status 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →